NCT01008462 · OUTCOME

Non-relapse Mortality (NRM)

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia · Source last updated 2019-06-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 200 days and 1 Year post-allograft

What was measured

Number of patients with non-relapse mortalities.

Analysis population: Two patients are not evaluable for GVHD due to disease progression; they failed the study and did not receive the allogeneic transplantation.

Groups in this outcome

Treatment (Autologous HCT, Donor HCT)

Allogeneic Bone Marrow Transplantation: Undergo donor HCT Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT Carmustine: Given IV Cyclophosphamide: Given IV Cytarabine: Given IV Etoposide: Given IV Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative study Melphalan: Given IV Mycophenolate Mofetil: Given PO Peripheral Blood Stem Cell Transplantation: Undergo donor HCT Tacrolimus: Given IV or PO Total-Body Irradiation: Undergo TBI

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Autologous HCT, Donor HCT)	14

Reported measurements

200 days

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Autologous HCT, Donor HCT)	0	Not reported	Not reported	Not reported	Not reported

1 Year

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Autologous HCT, Donor HCT)	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0
title
200 days
categories
measurements
group Id
OG000
value
1
title
1 Year

denoms

counts
group Id
OG000
value
14
units
Participants

description

Number of patients with non-relapse mortalities.

groups

description
Allogeneic Bone Marrow Transplantation: Undergo donor HCT Allogeneic Hematopoietic Stem Cell Transplantation: Undergo donor HCT Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSC transplant Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation: Undergo autologous-donor tandem HCT Carmustine: Given IV Cyclophosphamide: Given IV Cytarabine: Given IV Etoposide: Given IV Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative study Melphalan: Given IV Mycophenolate Mofetil: Given PO Peripheral Blood Stem Cell Transplantation: Undergo donor HCT Tacrolimus: Given IV or PO Total-Body Irradiation: Undergo TBI
id
OG000
title
Treatment (Autologous HCT, Donor HCT)

param Type

COUNT_OF_PARTICIPANTS

population Description

Two patients are not evaluable for GVHD due to disease progression; they failed the study and did not receive the allogeneic transplantation.

reporting Status

POSTED

time Frame

200 days and 1 Year post-allograft

title

Non-relapse Mortality (NRM)

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice